GlassScriptPhysician profile
Manny P Silis
NPI 1407932635
$8,018.38
in general payments reported to CMS, 2019-2025
49 companies · $982 in 2025
The $982 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $1,156 · 2021: $1,503 · 2022: $1,149 · 2023: $965 · 2024: $1,226 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139 · Entertainment: $34.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.81 |
| Entertainment | $34.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,170.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,118.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $636.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $504.20 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Lilly USA, LLC | $482.20 | 2019-2025 | Jardiance, Mounjaro |
| Amgen INC. | $349.53 | 2019-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $291.38 | 2019-2025 | Ubrelvy |
| Esperion Therapeutics, INC. | $284.01 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $258.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $256.99 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $248.32 | 2019-2025 | |
| Abbott Laboratories | $214.41 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $199.33 | 2019-2024 | Cresemba, Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $170.43 | 2023-2024 | Austedo Xr |
| Horizon Therapeutics Plc | $167.28 | 2021-2023 | Krystexxa |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manny Silis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.